150 related articles for article (PubMed ID: 11520780)
1. Thrombopoietin therapy increases platelet yields in healthy platelet donors.
Kuter DJ; Goodnough LT; Romo J; DiPersio J; Peterson R; Tomita D; Sheridan W; McCullough J
Blood; 2001 Sep; 98(5):1339-45. PubMed ID: 11520780
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
Goodnough LT; Kuter DJ; McCullough J; Slichter SJ; DiPersio J; Romo J; Peterson R; Smith KJ; Raife T; Tomita D; Armstrong S
Blood; 2001 Sep; 98(5):1346-51. PubMed ID: 11520781
[TBL] [Abstract][Full Text] [Related]
3. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
[TBL] [Abstract][Full Text] [Related]
4. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
[TBL] [Abstract][Full Text] [Related]
5. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
Geissler K; Yin JA; Ganser A; Sanz MA; Szer J; Raghavachar A; Hoelzer D; Martinez C; Taylor K; Kanz L; To LB; Archimbaud E
Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
Nakamura M; Toombs CF; Duarte IG; Ronson RS; Schmarkey LS; Katzmark SL; Robinson J; Dillehay DL; Vinten-Johansen J; Guyton RA
Ann Thorac Surg; 1998 Oct; 66(4):1216-23. PubMed ID: 9800809
[TBL] [Abstract][Full Text] [Related]
9. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
10. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
11. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
[TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant human megakaryocyte growth and development factor coupled with polyethylene glycol on the platelet storage lesion.
Snyder E; Perrotta P; Rinder H; Baril L; Nichol J; Gilligan D
Transfusion; 1999 Mar; 39(3):258-64. PubMed ID: 10204587
[TBL] [Abstract][Full Text] [Related]
13. The use of PEG-rhuMGDF in platelet apheresis.
Kuter DJ
Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195
[TBL] [Abstract][Full Text] [Related]
14. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.
Nomura S; Dan K; Hotta T; Fujimura K; Ikeda Y
Blood; 2002 Jul; 100(2):728-30. PubMed ID: 12091377
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
Archimbaud E; Ottmann OG; Yin JA; Lechner K; Dombret H; Sanz MA; Heil G; Fenaux P; Brugger W; Barge A; O'Brien-Ewen C; Matcham J; Hoelzer D
Blood; 1999 Dec; 94(11):3694-701. PubMed ID: 10572081
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.
Schiffer CA; Miller K; Larson RA; Amrein PC; Antin JH; Zani VJ; Stone RM
Blood; 2000 Apr; 95(8):2530-5. PubMed ID: 10753831
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
Basser RL; Underhill C; Davis I; Green MD; Cebon J; Zalcberg J; MacMillan J; Cohen B; Marty J; Fox RM; Begley CG
J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133
[TBL] [Abstract][Full Text] [Related]
19. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice.
Ulich TR; del Castillo J; Senaldi G; Cheung E; Roskos L; Young J; Molineux G; Guo J; Schoemperlen J; Munyakazi L; Murphy-Filkins R; Tarpley JE; Toombs CF; Kaufman S; Yin S; Nelson AG; Nichol JL; Sheridan WP
Exp Hematol; 1999 Jan; 27(1):117-30. PubMed ID: 9923450
[TBL] [Abstract][Full Text] [Related]
20. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
